Credit Suisse raised the price target for the AbbVie Inc. (NYSE:ABBV) stock to “an Outperform”. The rating was released on November 18, 2022, according to finviz. The research report from Atlantic Equities has downgraded the stock from Overweight to Neutral, with a price target set at $162. The stock was initiated by SVB Leerink, who disclosed in a research note on May 23, 2022, to Underperform and set the price objective to $140. In their research brief published May 06, 2022, Daiwa Securities analysts downgraded the AbbVie Inc. stock from Outperform to Neutral with a price target of $150.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of AbbVie Inc. (NYSE:ABBV) raised 1.37% to close Monday’s market session at $157.11, higher as compared to yesterday’s close. The stock price fluctuated between $154.43 and $158.629 throughout the trading session with the volume trading being 6491715 shares, which represented a significant variation when compared to the three months average volume of 5.47 million shares. The firm’s stock price fluctuated 3.54% within the last five trades and 6.83% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 6.13% in the last 6 months and 13.01% was added to its value over the previous 3 months. ABBV stock is trading at a margin of 5.10%, 8.47% and 5.93% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ABBV deals in the Healthcare domain. The stock is trading -10.69 percent below its 52-week high and 36.61 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 29.8. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does AbbVie Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 30.60 percent and the profit margin is 23.10 percent, and the company has reported a gross margin of 71.20 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $272.79 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for AbbVie Inc. (NYSE:ABBV) is 20.93. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 13.68. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 4.72 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 17.40, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.11 percent of AbbVie Inc. shares are owned by insiders, and 70.90 percent are held by financial institutions. SEVERINO MICHAEL, the Vice Chairman at AbbVie Inc. (ABBV) has sold 79,801 shares of firm on May 23 at a price of $150.90 against the total amount of $12.04 million. In another inside trade, SEVERINO MICHAEL, Vice Chairman of AbbVie Inc. (NYSE:ABBV) sold 100,000 shares of the firm on May 17 for a total worth of $15.4 million at a price of $154.04. An inside trade which took place on May 16, EVP, Chief Strategy Officer of AbbVie Inc. Gosebruch Henry O sold 83,960 shares of firm against total price of $13.01 million at the cost of $155.00 per share.